Medicare begins covering weight-loss drugs July 1

What This is

• Starting July 1, Medicare will begin covering certain GLP-1 weight-loss drugs for some Part D beneficiaries through a limited Bridge pilot program.
• Eligible enrollees can access Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay under the Medicare GLP-1 Bridge demonstration.
• The program requires prior authorization and applies only to people who meet body-mass-index and related health-condition criteria.
• Awareness of the new coverage appears low among seniors, and outreach has focused on clinicians and pharmacies rather than broad advertising.
• Clinics and pharmacies are preparing for heavy demand, and some doctors and advocates warn about delays, limited supply, and what happens when the pilot ends.

Why This Matters

• Whether Medicare pays for obesity drugs signals if obesity is treated like other chronic diseases in U.S. health policy.
• Subsidized access for millions could improve health, but it also increases taxpayer spending and intensifies pressure to lower drug prices.
• Tight eligibility rules and prior-approval paperwork can decide who gets care in practice, not just in theory.
• A temporary benefit can leave patients facing health and financial risks if they start a drug and then lose coverage.